Aristocratic Culture and the Pursuit of Science : The De Broglies in Modern France

Louis de Broglie received the Nobel Prize in Physics in 1929 following experimental confirmation of his theory of the wave properties of the electron. De Broglie was an anomaly among twentieth-century physicists: he was a prince by birth who would become the seventh duc de Broglie. What did it mean to be an aristocrat in an age of science? This essay explores aristocratic culture in France in the early twentieth century and examines the family life, education, scientific practices, and social values of Louis de Broglie, his brother Maurice, who was a distinguished experimental physicist, and their sister Pauline, who became a well-known novelist and literary scholar after her scientific interests were discouraged.Copyrighted and originally published by the University of Chicago Press on behalf of the History of Science Society and can be found at: http://www.jstor.org/action/showPublication?journalCode=isi

Historical Sources of Science-as-Social-Practice: Michael Polanyi's Berlin

Historians and sociologists of science often identify the efflorescence of social stud ies of science with the work of postwar American intellectuals such as Robert K. Merton and Thomas S. Kuhn. They often also refer to the views of Michael Polanyi (1891-1976) on the roles of tacit knowledge, apprenticeship, social tradition, and intellectual dogmas (or what Kuhn popularized as "paradigms") in the construction of scientific knowledge. The roots of Polanyi's views on the social nature of sci ence and his insistence on the need for scientists' autonomy in managing their own affairs lie specifically in his career experiences as a physical chemist from 1920 to 1933 in the Kaiser-Wilhelm-Gesellschaft Institutes in Berlin-Dahlem. Polanyi worked in an institution in which scientific research was supported by an array of state, industrial, and philanthropic funds, but in which he and his colleagues enjoyed substantial autonomy in their everyday research. His own successes and failures in the fields of physical chemistry, x-ray crystallography, and solid-state chemistry led him to reflect upon the everyday practices of normal science and to stress the role of the ordinary rather than the revolutionary scientist in the production of scientific knowledge. Polanyi's views lend insight into the character of German science and the research institutes in Berlin-Dahlem in the late 19th and early 20th century.Keywords: Michael Polanyi, Kaiser-Wilhelm-Institute for Physical Chemistry, Scientific practice, German science, Thomas Kuhn, Scientific communit

Scientific Biography: History of Science by Another Means?

Biography is one of the most popular categories of books—and indeed the most popular category among nonfiction books, according to one British poll. Thus, biography offers historians of science an opportunity to reach a potentially broad audience. This essay examines approaches typical of different genres of scientific biography, including historians’ motivations in their choices of biographical subject and their decisions about strategies for reconstruction of the biographical life. While historians of science often use biography as a vehicle to analyze scientific processes and scientific culture, the most compelling scientific biographies are ones that portray the ambitions, passions, disappointments, and moral choices that characterize a scientist’s life

Book Reviews

Creating a Local History Archive at Your Public Library. Faye Phillips. Paper Cadavers: The Archives of Dictatorship in Guatemala. Kirsten Weld. The Silence of the Archives. David Thomas, Simon Fowler, and Valerie Johnson. The Bad-Ass Librarians of Timbuktu and Their Race to Save the World\u27s Most Precious Manuscripts. Joshua Hammer. The International Business Archives Handbook: Understanding and Managing the Historical Records of Business. Edited by Alison Turton. Putting Descriptive Standards to Work. Edited by Kris Kiesling and Christopher J. Prom. Moving Image and Sound Collections for Archivists. Anthony Cocciolo

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

Background From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and ravulizumab, a monoclonal inhibitor of complement C5 activation, as an adjunct to standard of care for the treatment of adult patients hospitalised with COVID-19. Methods TACTIC-R was a phase 4, randomised, parallel-arm, open-label platform trial that was undertaken in the UK with urgent public health designation to assess the potential of repurposing immunosuppressants for the treatment of severe COVID-19, stratified by a risk score. Adult participants (aged ≥18 years) were enrolled from 22 hospitals across the UK. Patients with a risk score indicating a 40% risk of admission to an intensive care unit or death were randomly assigned 1:1:1 to standard of care alone, standard of care with baricitinib, or standard of care with ravulizumab. The composite primary outcome was the time from randomisation to incidence (up to and including day 14) of the first event of death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure. The primary interim analysis was triggered when 125 patient datasets were available up to day 14 in each study group and we included in the analysis all participants who were randomly assigned. The trial was registered on ClinicalTrials.gov (NCT04390464). Findings Between May 8, 2020, and May 7, 2021, 417 participants were recruited and randomly assigned to standard of care alone (145 patients), baricitinib (137 patients), or ravulizumab (135 patients). Only 54 (39%) of 137 patients in the baricitinib group received the maximum 14-day course, whereas 132 (98%) of 135 patients in the ravulizumab group received the intended dose. The trial was stopped after the primary interim analysis on grounds of futility. The estimated hazard ratio (HR) for reaching the composite primary endpoint was 1·11 (95% CI 0·62–1·99) for patients on baricitinib compared with standard of care alone, and 1·53 (0·88–2·67) for ravulizumab compared with standard of care alone. 45 serious adverse events (21 deaths) were reported in the standard-of-care group, 57 (24 deaths) in the baricitinib group, and 60 (18 deaths) in the ravulizumab group. Interpretation Neither baricitinib nor ravulizumab, as administered in this study, was effective in reducing disease severity in patients selected for severe COVID-19. Safety was similar between treatments and standard of care. The short period of dosing with baricitinib might explain the discrepancy between our findings and those of other trials. The therapeutic potential of targeting complement C5 activation product C5a, rather than the cleavage of C5, warrants further evaluation

Michael Polanyi and his generation: origins of the social construction of science

In Michael Polanyi and His Generation, Mary Jo Nye investigates the role that Michael Polanyi and several of his contemporaries played in the emergence of the social turn in the philosophy of science. This turn involved seeing science as a socially based enterprise that does not rely on empiricism and reason alone but on social communities, behavioral norms, and personal commitments. Nye argues that the roots of the social turn are to be found in the scientific culture and political events of Europe in the 1930s, when scientific intellectuals struggled to defend the universal status of scientific knowledge and to justify public support for science in an era of economic catastrophe, Stalinism and Fascism, and increased demands for applications of science to industry and social welfare. At the center of this struggle was Polanyi, who Nye contends was one of the first advocates of this new conception of science. Nye reconstructs Polanyi’s scientific and political milieus in Budapest, Berlin, and Manchester from the 1910s to the 1950s and explains how he and other natural scientists and social scientists of his generation—including J. D. Bernal, Ludwik Fleck, Karl Mannheim, and Robert K. Merton—and the next, such as Thomas Kuhn, forged a politically charged philosophy of science, one that newly emphasized the social construction of science

University of California Press eScholarship editions

How did chemistry and physics acquire their separate identities, and are they on their way to losing them again? Mary Jo Nye has written a graceful account of the historical demarcation of chemistry from physics and subsequent reconvergences of the two, from Lavoisier and Dalton in the late eighteenth century to Robinson, Ingold, and Pauling in the mid-twentieth century.Using the notion of a disciplinary "identity" analogous to ethnic or national identity, Nye develops a theory of the nature of disciplinary structure and change. She discusses the distinctive character of chemical language and theories and the role of national styles and traditions in building a scientific discipline. Anyone interested in the history of scientific thought will enjoy pondering with her the question of whether chemists of the mid-twentieth century suspected chemical explanation had been reduced to physical laws, just as Newtonian mechanical philosophers had envisioned in the eighteenth century